Previous 10 | Next 10 |
Odyssey is a medical company developing PRV-002, a novel compound for the treatment of concussion Between 75-83% of all the cases of traumatic brain injury (“TBI”) among U.S. service members have been classified as mild (“mTBI”), commonly termed “concu...
Odyssey Health (OTC: ODYY) , formerly Odyssey Group International and a company focused on developing unique, life-saving medical products, is featured in the latest interview released by the RedChip Money Report and aired on Bloomberg TV. The interview with Odyssey Health CEO Michael Redmo...
Las Vegas, NV, June 08, 2022 (GLOBE NEWSWIRE) -- RedChip Companies will air a new C-Level interview with Odyssey Health, Inc. (OTC Pink: ODYY), f/k/a Odyssey Group International, Inc. on The RedChip Money Report® on Bloomberg TV, this Saturday, June 11, at 7 p.m. Eastern Time (ET). Blo...
Odyssey Health is a medical company focused on unique, life-saving medical products that offer clinical advantages to conditions with unmet needs The subject of an ongoing Phase I clinical trial, Odyssey’s PRV-002 is a novel compound for treating concussion, which currently has n...
Odyssey Health (OTC: ODYY) is a medical technology company focused on developing lifesaving products that offer technological and clinical advantages over current standards of care. Guided by a senior management team with significant experience relating to refining acquired technologies, b...
Odyssey Health (OTC: ODYY) , formerly Odyssey Group International and a company focused on developing unique, life-saving medical products, has completed the safety evaluation for cohort 1 of its phase 1 clinical trial, which is being conducted by Nucleus Network, a leading clinical researc...
Irvine, CA, June 01, 2022 (GLOBE NEWSWIRE) -- Odyssey Health, Inc. (OTC Pink: ODYY), f/k/a Odyssey Group International, Inc., a company focused on developing unique, life-saving medical products, today announced positive safety findings from Cohort I of their Phase I clinical trial. Odyssey...
Odyssey boasts a diverse development portfolio spanning both pharmaceutical candidates and medical devices The company is evaluating PRV-002 for the treatment of concussion, a dramatically underserved indication that currently has no FDA-approved drug With PRV-001, Odyssey aims to rec...
Odyssey Health (OTC: ODYY) , f/k/a Odyssey Group International Inc., a company focused on developing unique, life-saving medical products, has announced positive results from the first group of patients dosed with PRV-002 in its phase I clinical trial. According to the update, Odysseyȁ...
Irvine, CA, May 05, 2022 (GLOBE NEWSWIRE) -- Odyssey Health, Inc. (OTC Pink: ODYY), f/k/a Odyssey Group International, Inc., a company focused on developing unique, life-saving medical products, today announced positive results from the first group of patients dosed with PRV-002, in their P...
News, Short Squeeze, Breakout and More Instantly...
Odyssey Group International Inc Company Name:
ODYY Stock Symbol:
OTCMKTS Market:
Odyssey Group International Inc Website:
LAS VEGAS, NV / ACCESSWIRE / March 27, 2024 / Odyssey Health, Inc. (OTCQB:ODYY) , formerly Odyssey Group International, Inc., (the "Company") a company focused on developing unique, life-enhancing medical products, recently filed its quarterly report for the quarter ended January 31, 2024. The ...
LAS VEGAS, NV / ACCESSWIRE / January 2, 2024 / Odyssey Health, Inc. (OTCQB:ODYY) ("Odyssey" or the "Company") today announces the closing of the definitive Asset Purchase Agreement, that was entered into on October 4, 2023, with Oragenics, Inc., (OGEN:NYSE American) under which Oragenics acquire...
LAS VEGAS, NV / ACCESSWIRE / December 12, 2023 / Odyssey Health, Inc. ( OTCOB:ODYY ), a company focused on developing unique, life-enhancing medical products including a drug treatment intended to treat concussion, announces that it has received stockholder approval for the sale of its neurologi...